GIP and metabolic disease: More recently, novel co-agonists of GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon have also been approved or are under evaluation for the treatment of diabetes and associated metabolic diseases, holding potential for cardiovascular risk reduction.